ASSOCIATION BETWEEN APPARENT DIFFUSION COEFFICIENT AND KI67 IN BRAIN TUMORS: A SYSTEMATIC REVIEW
https://doi.org/10.21294/1814-4861-2021-20-2-110-117
Abstract
Certain histological variants of tumors have a correlation between the values of the apparent diffusion coefficients (AdC), cell density and the proliferative activity index MIB-I (Ki67). The results of studies on the relationship between the values of the AdC and the Ki67 index in brain tumors are ambiguous and largely contradictory.
The purpose of this study was to perform a systematic review based on the results of clinical studies that examined the relationship between AdC values and the Ki67 proliferative activity index in brain tumors.
Material and Methods. Clinical studies were searched in the databases pubmed, EMBASE, Cohrane Library and eLibrary published from January 2000 to January 2020, which studied the relationship between AdC values and the Ki67 proliferative activity index in brain tumors.
Results. A systematic review included 17 retrospective cohort nonrandomized clinical studies. The average value of the coefficient of reliable correlation between AdC and the mitotic index Ki67 in the group of meningiomas was -0.493. The indicated dependence was more often found in groups of typical (MI) and atypical (MII) brain meningiomas. The average coefficient of statistically significant correlation between the studied parameters in the group of brain gliomas was -0.443. The relationship between the AdC values and the Ki67 proliferative activity index was observed both in the glioma group of low (GI–II) and high (GIII–IV) grade of malignancy. In groups of patients with pituitary adenomas, primary lymphomas and brain metastases, the relationship between the studied parameters was not reliably confirmed.
Conclusion. The use of diffusion-weighted magnetic resonance imaging
techniques with subsequent calculation of AdC values can be recommended for use in the clinical practice of oncologists in order to assess the proliferative potential of brain meningiomas and gliomas.
Keywords
About the Authors
I. A. StepanovRussian Federation
MD, Postgraduate, Department of Neurosurgery and Innovative Medicine
Russia, 664003, Irkutsk, Krasnogo Vosstaniya Street, 1
M. A. Shameeva
Russian Federation
Clinical Resident, Department of Neurosurgery and Innovative Medicine
Russia, 664003, Irkutsk, Krasnogo Vosstaniya Street, 1
D. B. Kruchinin
Russian Federation
Clinical Resident, Department of Neurosurgery and Innovative Medicine
Russia, 664003, Irkutsk, Krasnogo Vosstaniya Street, 1
References
1. Mannelli L., Nougaret S., Vargas H.A., Do R.K. Advances in diffusion-weighted imaging. Radiol Clin North Am. 2015; 53(3): 569–581. doi: 10.1016/j.rcl.2015.01.002.
2. Guadilla I., Calle D., López-Larrubia P. Diffusion-Weighted Magnetic Resonance Imaging. Methods Mol Biol. 2018; 1718: 89– 101. doi: 10.1007/978-1-4939-7531-0_6.
3. Salama G.R., Heier L.A., Patel P., Ramakrishna R., Magge R., Tsiouris A.J. Diffusion Weighted/Tensor Imaging, Functional MRI and Perfusion Weighted Imaging in Glioblastoma-Foundations and Future. Front Neurol. 2018 Jan 22; 8: 660. doi: 10.3389/fneur.2017.00660.
4. Barral M., Eveno C., Hoeffel C., Boudiaf M., Bazeries P., Foucher R., Pocard M., Dohan A., Soyer P. Diffusion-weighted magnetic resonance imaging in colorectal cancer. J Visc Surg. 2016 Nov; 153(5): 361–369. doi: 10.1016/j.jviscsurg.2016.08.004.
5. Messiou C., Kaiser M. Whole body diffusion weighted MRI--a new view of myeloma. Br J Haematol. 2015 Oct; 171(1): 29–37. doi: 10.1111/bjh.13509.
6. Vu L.N., Morelli J.N., Szklaruk J. Basic MRI for the liver oncologists and surgeons. J Hepatocell Carcinoma. 2018; 5: 37–50. doi: 10.2147/JHC.S154321.
7. Manoharan D., Das C.J., Aggarwal A., Gupta A.K. Diffusion weighted imaging in gynecological malignancies present and future. World J Radiol. 2016 Mar 28; 8(3): 288–97. doi: 10.4329/wjr.v8.i3.288.
8. Zakaria R., Jenkinson M.D. Diffusion weighted MRI is a promising imaging biomarker in brain metastases. J Neurooncol. 2015 Jan; 121(2): 421–2. doi: 10.1007/s11060-014-1642-8.
9. Huang J., Luo J., Peng J., Yang T., Zheng H., Mao C. Cerebral schistosomiasis: diffusion-weighted imaging helps to differentiate from brain glioma and metastasis. Acta Radiol. 2017 Nov; 58(11): 13711377. doi: 10.1177/0284185116687173.
10. Padhani A.R., Liu G., Koh D.M., Chenevert T.L., Thoeny H.C., Takahara T., Dzik-Jurasz A., Ross B.D., Van Cauteren M., Collins D., Hammoud D.A., Rustin G.J., Taouli B., Choyke P.L. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009 Feb; 11(2): 102–25. doi: 10.1593/neo.81328.
11. Wang J., Takashima S., Takayama F., Kawakami S., Saito A., Matsushita T., Momose M., Ishiyama T. Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology. 2001 Sep; 220(3): 621–30. doi: 10.1148/radiol.2202010063.
12. Kyriazi S., Collins D.J., Messiou C., Pennert K., Davidson R.L., Giles S.L., Kaye S.B., Desouza N.M. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients. Radiology. 2011 Oct; 261(1): 182–92. doi: 10.1148/radiol.11110577.
13. Bollineni V.R., Kramer G., Liu Y., Melidis C., deSouza N.M. A literature review of the association between diffusion-weighted MRI derived apparent diffusion coefficient and tumour aggressiveness in pelvic cancer. Cancer Treat Rev. 2015 Jun; 41(6): 496–502. doi: 10.1016/j.ctrv.2015.03.010.
14. Papaevangelou E., Almeida G.S., Jamin Y., Robinson S.P., deSouza N.M. Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosisinducing therapy. Br J Cancer. 2015 Apr 28; 112(9): 1471–9. doi: 10.1038/bjc.2015.134.
15. Sun Y.S., Cui Y., Tang L., Qi L.P., Wang N., Zhang X.Y., Cao K., Zhang X.P. Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient. Am J Roentgenol. 2011 Jul; 197(1): W23–9. doi: 10.2214/AJR.10.4912.
16. Goense L., Heethuis S.E., van Rossum P.S.N., Voncken F.E.M., Lagendijk J.J.W., Lam M.G.E.H., Terhaard C.H., van Hillegersberg R., Ruurda J.P., Mook S., van Lier A.L.H.M.W., Lin S.H., Meijer G.J. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer. Nucl Med Commun. 2018; 39(1): 60–67. doi: 10.1097/MNM.0000000000000771.
17. Kovač J.D., Galun D., Đurić-Stefanović A., Lilić G., Vasin D., Lazić L., Mašulović D., Šaranović Đ. Intrahepatic mass-forming cholangiocarcinoma and solitary hypovascular liver metastases: is the differential diagnosis using diffusion-weighted MRI possible? Acta Radiol. 2017 Dec; 58(12): 1417–1426. doi: 10.1177/0284185117695666.
18. Driessen J.P., Caldas-Magalhaes J., Janssen L.M., Pameijer F.A., Kooij N., Terhaard C.H., Grolman W., Philippens M.E. Diffusion-weighted MR imaging in laryngeal and hypopharyngeal carcinoma: association between apparent diffusion coefficient and histologic findings. Radiology. 2014 Aug; 272(2): 456–63. doi: 10.1148/radiol.14131173.
19. Karaman A., Durur-Subasi I., Alper F., Araz O., Subasi M., Demirci E., Albayrak M., Polat G., Akgun M., Karabulut N. Correlation of diffusion MRI with the Ki67 index in non-small cell lung cancer. Radiol Oncol. 2015 Aug 21; 49(3): 250–5. doi: 10.1515/raon-2015-0032.
20. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009 Jul 21; 6(7): e1000100. doi: 10.1371/journal.pmed.1000100.
21. Byvaltsev V.A., Stepanov I.A., Kichigin A.I., Kanigin V.V., Stupak V.V. The role of diffusion-weighted MRI in differential diagnosis and prediction of survival in patients with brain metastases. Ann of the Russ Acad Med Sci. 2017; 72(6): 442–449. (in Russian). doi: 10.15690/vramn890.
22. Byvaltsev V.A., Stepanov I.A., Kichigin A.I., Antipina S.L. Diffusion-weighted MRI in the differential diagnosis of brain meningiomas. Siberian Journal of Oncology. 2017; 16(3): 19–26. (in Russian). doi: 10.21294/1814-4861-2017-16-3-19-26.
23. Byvaltsev V.A., Stepanov I.A., Kichigin A.I. The Value of Diffusion-weighted Magnetic Resonance Imaging in the Preoperative Evaluation of the Grade of Brain Gliomas. Journal of Radiology and Nuclear Medicine. 2019; 100(2): 102–110. (in Russian). doi: 10.20862/0042-4676-2019-100-2-102-110.
24. Gupta R.K., Cloughesy T.F., Sinha U., Garakian J., Lazareff J., Rubino G., Rubino L., Becker D.P., Vinters H.V., Alger J.R. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol. 2000 Dec; 50(3): 215–26. doi: 10.1023/a:1006431120031.
25. Schob S., Meyer J., Gawlitza M., Frydrychowicz C., Müller W., Preuss M., Bure L., Quäschling U., Hoffmann K.T., Surov A. DiffusionWeighted MRI Reflects Proliferative Activity in Primary CNS Lymphoma. PLoS One. 2016 Aug 29; 11(8): e0161386. doi: 10.1371/journal.pone.0161386.
26. Fatima Z., Motosugi U., Waqar A.B., Hori M., Ishigame K., Oishi N., Onodera T., Yagi K., Katoh R., Araki T. Associations among q-space MRI, diffusion-weighted MRI and histopathological parameters in meningiomas. Eur Radiol. 2013 Aug; 23(8): 2258–63. doi: 10.1007/s00330-013-2823-0.
27. Surov A., Gottschling S., Mawrin C., Prell J., Spielmann R.P., Wienke A., Fiedler E. Diffusion-Weighted Imaging in Meningioma: Prediction of Tumor Grade and Association with Histopathological Parameters. Transl Oncol. 2015 Dec; 8(6): 517–23. doi: 10.1016/j.tranon.2015.11.012.
28. Yan R., Haopeng P., Xiaoyuan F., Jinsong W., Jiawen Z., Chengjun Y., Tianming Q., Ji X., Mao S., Yueyue D., Yong Z., Jianfeng L., Zhenwei Y. Non-Gaussian diffusion MR imaging of glioma: comparisons of multiple diffusion parameters and correlation with histologic grade and MIB-1 (Ki67 labeling) index. Neuroradiology. 2016; 58(2): 121–32. doi: 10.1007/s00234-015-1606-5.
29. Bai Y., Lin Y., Zhang W., Kong L., Wang L., Zuo P., Vallines I., Schmitt B., Tian J., Song X., Zhou J., Wang M. Noninvasive amide proton transfer magnetic resonance imaging in evaluating the grading and cellularity of gliomas. Oncotarget. 2017 Jan 24; 8(4): 5834–42. doi: 10.18632/oncotarget.13970.
30. Baskan O., Silav G., Bolukbasi F.H., Canoz O., Geyik S., Elmaci I. Relation of apparent diffusion coefficient with Ki67 proliferation index in meningiomas. Br J Radiol. 2016; 89(1057): 20140842. doi: 10.1259/bjr.20140842.
31. Berghoff A.S., Spanberger T., Ilhan-Mutlu A., Magerle M., Hutterer M., Woehrer A., Hackl M., Widhalm G., Dieckmann K., Marosi C., Birner P., Prayer D., Preusser M. Preoperative diffusion-weighted imaging of single brain metastases correlates with patient survival times. PLoS One. 2013; 8(2): e55464. doi: 10.1371/journal.pone.0055464.
32. Mahmoud O.M., Tominaga A., Amatya V.J., Ohtaki M., Sugiyama K., Sakoguchi T., Kinoshita Y., Takeshima Y., Abe N., Akiyama Y., El-Ghoriany A.I., Abd Alla A.K., El-Sharkawy M.A., Arita K., Kurisu K., Yamasaki F. Role of PROPELLER diffusion-weighted imaging and apparent diffusion coefficient in the evaluation of pituitary adenomas. Eur J Radiol. 2011 Nov; 80(2): 412–7. doi: 10.1016/j.ejrad.2010.05.023.
33. Sunwoo L., Choi S.H., Park C.K., Kim J.W., Yi K.S., Lee W.J., Yoon T.J., Song S.W., Kim J.E., Kim J.Y., Kim T.M., Lee S.H., Kim J.H., Sohn C.H., Park S.H., Kim I.H., Chang K.H. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. J Magn Reson Imaging. 2013; 37(2): 351–8. doi: 10.1002/jmri.23838.
34. Tamrazi B., Pekmezci M., Aboian M., Tihan T., Glastonbury C.M. Apparent diffusion coefficient and pituitary macroadenomas: pre-operative assessment of tumor atypia. Pituitary. 2017 Apr; 20(2): 195–200. doi: 10.1007/s11102-016-0759-5.
35. Zhang Y., Zhang Q., Wang X.X., Deng X.F., Zhu Y.Z. Value of pretherapeutic DWI in evaluating prognosis and therapeutic effect in immunocompetent patients with primary central nervous system lymphoma given high-dose methotrexate-based chemotherapy: ADC-based assessment. Clin Radiol. 2016 Oct; 71(10): 1018–29. doi: 10.1016/j.crad.2016.05.017.
36. Tang Y., Dundamadappa S.K., Thangasamy S., Flood T., Moser R., Smith T., Cauley K., Takhtani D. Correlation of apparent diffusion coefficient with Ki67 proliferation index in grading meningioma. Am J Roentgenol. 2014 Jun; 202(6): 1303–8. doi: 10.2214/AJR.13.11637.
37. Ginat D.T., Mangla R., Yeaney G., Wang H.Z. Correlation of diffusion and perfusion MRI with Ki67 in high-grade meningiomas. Am J Roentgenol. 2010 Dec; 195(6): 1391–5. doi: 10.2214/AJR.10.4531.
38. Booth D.G., Earnshaw W.C. Ki67 and the Chromosome Periphery Compartment in Mitosis. Trends Cell Biol. 2017 Dec; 27(12): 906916. doi: 10.1016/j.tcb.2017.08.001.
39. Schellhaus A.K., De Magistris P., Antonin W. Nuclear Reformation at the End of Mitosis. J Mol Biol. 2016 May 22; 428(10 Pt A): 1962–85. doi: 10.1016/j.jmb.2015.09.016.
40. Surov A., Meyer H.J., Höhn A.K., Behrmann C., Wienke A., Spielmann R.P., Garnov N. Correlations between intravoxel incoherent motion (IVIM) parameters and histological findings in rectal cancer: preliminary results. Oncotarget. 2017 Mar; 8(13): 21974–983. doi: 10.18632/oncotarget.15753.
41. Mitchison J.M. Growth during the cell cycle. Int Rev Cytol. 2003; 226: 165258. doi: 10.1016/s0074-7696(03)01004-0.
42. Valentine M.T., Perlman Z.E., Mitchison T.J., Weitz D.A. Mechanical properties of Xenopus egg cytoplasmic extracts. Biophys J. 2005; 88(1): 680–9. doi: 10.1529/biophysj.104.048025.
43. Surov A., Meyer H.J., Wienke A. Associations between apparent diffusion coefficient (ADC) and KI67 in different tumors: a meta-analysis. Part 1: ADCmean. Oncotarget. 2017 Aug; 8(43): 75434–44. doi: 10.18632/oncotarget.20406.
Review
For citations:
Stepanov I.A., Shameeva M.A., Kruchinin D.B. ASSOCIATION BETWEEN APPARENT DIFFUSION COEFFICIENT AND KI67 IN BRAIN TUMORS: A SYSTEMATIC REVIEW. Siberian journal of oncology. 2021;20(2):110-117. (In Russ.) https://doi.org/10.21294/1814-4861-2021-20-2-110-117